Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
NCT ID: NCT00318643
Last Updated: 2021-10-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
27 participants
INTERVENTIONAL
2006-03-30
2009-08-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of escalating doses of Chemophase in combination with mitomycin (mitomycin C, MMC) administered as weekly intravesical instillations for five weeks, and
2. establish the dose of Chemophase with MMC recommended for future studies.
The secondary objectives of this study are to:
1. assess the pharmacokinetics of intravesical administration of MMC alone and in combination with intravesical administration of Chemophase,
2. for those participants treated at the MTD, assess the safety and tolerability of intravesical administration of MMC with Chemophase over up to 7 additional maintenance treatments every 3 months following the initial six weekly instillations, and
3. observe participants for any preliminary evidence of anti-tumor activity of MMC and Chemophase when combined.
Study participants will receive six weekly study treatments administered intravesically (at Weeks 1 through 6) followed by post-treatment evaluations, at Weeks 8 and 12. The 12 participants treated at MTD will continue to receive combination therapy every three months until the end of Year 2 or until the time of documented tumor recurrence, whichever occurs first. For other participants, long-term follow-up after Week 12 will consist of disease monitoring of participants by telephone and will be performed every three months beginning three months after last study treatment for two years and then every six months thereafter, until bladder tumor recurrence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SEQUENTIAL
PREVENTION
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: MMC plus Chemophase 20,000 U
Participants will receive 40 milligrams (mg) MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 20,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Cohort 2: MMC plus Chemophase 60,000 U
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 60,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Cohort 3: MMC plus Chemophase 200,000 U
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 200,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Cohort 4: MMC plus Chemophase 400,000 U
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 400,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Cohort 5: MMC plus Chemophase 800,000 U
Participants will receive 40 mg MMC intravesically on Day 1 of Week 1 followed by a combination of 40 mg MMC and 800,000 U Chemophase intravesically once weekly from Weeks 2 through 6.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Mitomycin C
intravesical administration
Chemophase
intravesical administration
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* TURBT within 42 days prior to Day 1/Week 1
* Karnofsky Performance Status greater than or equal to 80%
* Life expectancy at least 3 years
* 18 years or older
* A negative pregnancy test (if female of child-bearing potential)
* Acceptable liver function within 7 days defined as: bilirubin less than or equal to 1.5 times upper limit of normal, and aspartate aminotransferase (AST) Glutamic-oxalacetic transaminase (SGOT), alanine aminotransferase (ALT), glutamic-pyruvic transaminase (SGPT), and alkaline phosphatase \<= 2.5 times upper limit of normal
* Acceptable renal function within 7 days defined as: serum creatinine less than or equal to 1.5 times upper limit of normal, or calculated creatinine clearance greater than or equal to 40 milliliter (mL)/minute/1.73 meter\^2
* Acceptable hematologic status within 7 days defined as: absolute neutrophil count (ANC) greater than or equal to 2,500 cells/millimeter\^3, platelet count greater than or equal to 150,000/millileter\^3, and hemoglobin greater than or equal to 10.0 grams/deciliter.
* Urinalysis showing no clinically significant abnormalities except those attributable to bladder cancer.
* For men and women of child-producing potential, agreement to use an effective contraceptive method during the treatment period of the study.
* Signed, written Institutional Review Board (IRB)-approved informed consent
Exclusion Criteria
* Total bladder capacity estimated at cystoscopy to be less than 150 mL
* Urinary incontinence of a severity that would compromise the ability of the participant to retain the study drug intravesical instillation for two hours.
* Severe irritative voiding symptoms such as urgency, frequency, or nocturia
* Known other malignant disease except squamous or basal cell skin cancer unless the malignancy has been in complete remission off therapy for at least 5 years.
* Major surgery, other than TURBT and diagnostic surgery, within 28 days prior to Day 1/Week 1.
* Active, uncontrolled bacterial, viral, or fungal infections, including urinary tract infection.
* Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within one month prior to Day 1/Week 1 on study (two months for nitrosureas or MMC), unless given as standard treatment for bladder cancer and provided that patient is free of all treatment-related toxicities as of Day 1/Week 1.
* Known infection with human immunodeficiency virus (HIV)
* Known active infection with hepatitis B or hepatitis C
* Serious disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor (Halozyme).
* History of a hypersensitivity or idiosyncratic reaction to, or other contraindication to, mitomycin.
* Known allergy to bee or vespid venom
* Known coagulation disorder or bleeding tendency
* Treatment with heparin or anticipation of heparin treatment during the treatment period in this study.
* Unwillingness or inability to comply with procedures required in this protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Halozyme Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BCG Oncology
Phoenix, Arizona, United States
MedResearch
La Mesa, California, United States
Malcolm Randall Veterans Administration Urology Section (112-C)
Gainesville, Florida, United States
Advanced Research Institute
New Port Richey, Florida, United States
James A. Haley Veterans Hospital
Tampa, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
Sponsor's website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HZ2-05-01
Identifier Type: -
Identifier Source: org_study_id